Wednesday - ARVO

4083 – 4105 – Wednesday – Posters
Wednesday Posters
8:30 am – 10:15 am
Exhibit Hall A0001-A0047
Wednesday, May 08, 2013 8:30 AM-10:15 AM
Retina
413 AMD II, RE
Moderators: David R. Hinton and Diana V. Do
4083 — A0001 Pars Plana Vitrectomy,
Subretinal Injection of Recombinant Tissue
Plasminogen Activator and Intraocular Gas
Tamponade for Thick Submacular Hemorrhage
with Polypoidal Choroidal Vasculopathy.
Woohyok Chang, C. Cho, M. Sagong, H. Oh, J.
Park, D. Park, M. Kim, W. Gu, J. Son. Department
of Ophthalmology, Yeungnam Univ College of
Medicine, Daegu, Republic of Korea
4084 — A0002 The Effects of Docosahexaenoic
Acid (DHA) Dietary Supplementation on Retinal
Lipid Profile in a Mouse Model of Stargardt-like
Macular Dystrophy (STGD3). Mandy Hong 1 , S.
Kuny 1 , R. Bryant 1 , F. Gaillard 1 , M. Suh 2 , Y. Sauve 1 .
1
Ophthalmology, University of Alberta, Edmonton,
AB, Canada; 2 Human Nutritional Sciences,
University of Manitoba, Winnipeg, MB, Canada
4085 — A0003 In vivo Evaluation of Surface
Modified Expanded-polytetrafluroethylene
(ePTFE) Substrate as a Permanent Substrate
for Cell Transplantation. Shen Nian 1 , Z. Fu 1 , C.
M. Sheridan 3 , V. Kearns 3 , R. Williams 3 , S. Wong 1 ,
K. Vasilev 4 , A. Bachhuka 4 , A. C. Lo 1, 2 , W. W. Lai 1 .
1
Ophthalmology, University of Hong Kong, Hong
Kong, Hong Kong; 2 Research Centre of Heart,
Brain, Hormone and Healthy Aging, University of
Hong Kong, Hong Kong, Hong Kong; 3 Eye and
Vision Science, University of Liverpool, Liverpool,
United Kingdom; 4 Mawson Institute and School
of Advanced Manufacturing, University of South
Australia, Mawson Lakes, SA, Australia
4086 — A0004 Prevalence of Subretinal
Drusenoid Deposits in Age-Related Macular
Degeneration with Newly Diagnosed Choroidal
Neovascularization. Sandrine A. Zweifel, R. A.
Rieder, M. M. Kohler, R. Gambon. Department of
Ophthalmology, University Hospital Zurich, Zurich,
Switzerland
4087 — A0005 Autofluorescence and OCT of
Retinal pigment epithelial tears. Naoto Hanyuda,
T. Sato, R. Mukai, S. Kishi. Gunma University,
Maebashi, Japan *CR
4088 — A0006 Anatomic patterns and clinical
presentation of recurrence in ‘stable’ wet Age
Related Macular Degeneration (AMD) patients.
Fani Zacharaki, M. N. Chandran, N. Nair, P.
Vijayakumar, G. Menon. Frimley Park Hospital
NHS Foundation Trust, Frimley, United Kingdom
*CR
4089 — A0007 Detection and Quantification
of Autofluorescence Abnormalities in Patients
with Neovascular Macular Degeneration using
a Fully Automated Image Analysis Algorithm.
Kathryn L. Pepple, Q. Nie, S. S. Ong, S. W. Cousins.
Ophthalmology, Duke Eye Center, Durham, NC
*CR
4090 — A0008 Ranibizumab Leads to
Regression or Elimination of Choroidal
Neovascular Membranes in Most Eyes with
AMD: A HARBOR Subanalysis. Nikolas J.
London 1 , P. E. Tornambe 1 , L. Yau 2 , J. A. Nau 2 , L.
Tuomi 2 . 1 Retina Consultants San Diego, San Diego,
CA; 2 Genentech Inc., South San Francisco, CA
*CR, f
4091 — A0009 Anti-VEGF Gene Therapy for
Wet AMD: Phase I/II Safety and Pharmacology
Results. Elizabeth P. Rakoczy 1, 2 , M. Lai 1, 2 ,
C. Pierce 2 , A. L. Magno 2 , R. Samulski 3 , T. W.
Chalberg 4 , M. S. Blumenkranz 5 , I. Constable 1, 2 .
1
Centre for Ophthalmology and Visual Sciences,
The University of Western Australia, Perth, WA,
Australia; 2 Molecular Ophthalmology, Lions Eye
Institute, Perth, WA, Australia; 3 Gene Therapy
Centre, University of North Carolina, Chapel Hill,
NC; 4 Avalanche Biotechnologies, San Francisco,
CA; 5 Byers Eye Institute at Stanford, Palo Alto, CA
*CR, f
4092 — A0010 Polypoidal choroidal
vasculopathy in Caucasian patients. Stephen
Davis, A. Lauer, C. J. Flaxel. Oregon Health and
Science University, Casey Eye Institute, Portland,
OR *CR
4093 — A0011 Baseline characteristics and
response to intravitreal ranibizumab therapy for
age-related macular degeneration. Misa Suzuki,
N. Nagai, K. Izumi-Nagai, H. Shinoda, T. Koto,
A. Uchida, H. Mochimaru, K. Yuki, K. Tsubota, Y.
Ozawa. Ophthalmology, Keio University School of
Medicine, Tokyo, Japan *CR, f
4094 — A0012 Disease Activity in Disciform
Scars due to Age-Related Macular Degeneration
(AMD). Deborah Witkin 1 , J. B. Sanderson 1 , D.
Ferrara 2, 1 , E. Reichel 1 . 1 Ophthalmology, Tufts
Medical Center, Boston, MA; 2 Digital Angiography
Reading Center DARC, Great Neck, NY *CR
4095 — A0013 The Incidence of Neovascular
Subtypes in Newly Diagnosed Wet Age-Related
Macular Degeneration. Jesse J. Jung 1, 3 , L.
Xu 2, 5 , R. Gallego-Pinazo 2, 4 , S. Mrejen 2, 3 , M.
Marsiglia 2, 3 , S. Boddu 1 , K. Freund 1, 2 . 1 Department
of Ophthalmology, New York Univ School of
Med, New York, NY; 2 Vitreous Retina Macula
Consultants of New York, New York, NY; 3 LuEsther
T. Mertz Retinal Research Center, Manhattan
Eye, Ear, and Throat Hospital, New York, NY;
4
Department of Ophthalmology, University and
Polytechnic Hospital La Fe, Valencia, Spain; 5 St.
Vincent’s Medical Center, Bridgeport, CT *CR
4096 — A0014 Choroidal thickness change
following intravitreal bevacizumab therapy
for wet age-related macular degeneration: Six
months results. Sharif Y. El Emam, G. Barteselli, J.
Chhablani, S. Lee, I. Kozak, L. Cheng, W. Freeman.
Ophthalmology, Shiley Eye Center, UCSD, La
Jolla, CA *CR
4097 — A0015 The Relationship of Choroidal
Thickness to Scotopic Sensitivity in Agerelated
Macular Degeneration (AMD). Karl G.
Csaky 1, 3 , D. G. Birch 1, 2 , R. Gelman 1 , J. Felius 1 .
1
Ophthalmology, Retina Foundation of the
Southwest, Dallas, TX; 2 Ophthalmology, University
of Texas Southwestern Medical Center, Dallas, TX;
3
Texas Retina Associates, Dallas, TX *CR
4098 — A0016 Choroidal Thickness
following Anti-Vascular Endothelial Growth
Factor Therapy for Neovascular Age-Related
Macular Degeneration. Charlotte So, Z. Ravage.
Ophthalmology, Rush University Medical Center,
Chicago, IL
4099 — A0017 Correlation Between Changes
in Subfoveal Choroidal Thickness and 1-Year
Outcomes of Ranibizumab Therapy for
Polypoidal Choroidal Vasculopathy. Taiichi
Hikichi, H. Kitamei, S. Shioya, M. Higuchi, T.
Matsushita, S. Kosaka, R. Matsushita, K. Takami,
H. Ohtsuka. Ohtsuka Eye Hospital, Sapporo, Japan
4100 — A0018 Axial Length and Subfoveal
Choroidal Thickness in Individuals with Agerelated
Macular Degeneration (AMD). Chih
Ping Wang 1, 2 , C. Lai 1, 2 , J. Huang 1, 2 , C. Kuo 1, 2 .
1
Department of Ophthalmology, Chang Gung
Memorial Hospital, Chiayi, Chiayi County, Taiwan;
2
Chang Gung University, Taoyan, Taiwan
4101 — A0019 APE1/Ref-1 redox inhibitor
APX3330 modulates choroidal endothelial cells
by transcriptional regulation of NF-κB and
STAT3 activity. Xiaoxi Qiao 1 , Y. Li 1 , X. Liu 1 , T.
Zhou 1 , M. R. Kelley 2 , P. A. Edwards 1 , H. Gao 1 .
1
Ophthalmology, Henry Ford Health System,
Detroit, MI; 2 Herman B Wells Center for Pediatric
Research, Indiana University School of Medicine,
Indianapolis, IN *CR
4102 — A0020 Apolipoprotein mimetic Dual
Domain Peptide reduces Neutral Lipid Deposits
in murine Bruch’s Membrane. Armin Mohi, S.
Grisanti, M. Rudolf. Department of Ophthalmology,
University of Luebeck, Luebeck, Germany *CR
4103 — A0021 Identification of Human
Macular Tissue Antigens Recognized by Serum
Auto-Antibodies (auto-Abs) in Patients with
Age-Related Macular Degeneration (AMD).
Nataliya I. Lenchik 1, 2 , F. Giorgianni 3 , S. Beranova-
Giorgianni 3 , I. C. Gerling 1 , M. Z. Radic 4 , A.
Iannaccone 2 . 1 Medicine/Endocrinology, Univ.
Tennessee HSC, Memphis, TN; 2 Hamilton Eye
Institute, Univ. Tennessee HSC, Memphis, TN;
3
Pharmaceutical Sciences, Univ. Tennessee HSC,
Memphis, TN; 4 Microbiology, Immunology &
Biochemistry, Univ. Tennessee HSC, Memphis, TN
4104 — A0022 Early ocular lipid deposition
in a mouse model of hyperlipidemia and
atherosclerosis. Michaela K. Mathews, T. Albukh,
K. E. Duncan. Ophthalmology, Univ of Maryland,
Baltimore, Baltimore, MD
4105 — A0023 The role of systemic infection
and response to Ranibizumab therapy for Age
Related Macular Degeneration (AMD). Charles
O. Pierce 1, 2 , M. Nelson 2 , J. Scott 1 , H. L. Griffiths 1 ,
N. L. James 1 , H. A. Thomson 1 , A. J. Cree 1 , A. J.
Lotery 1, 2 . 1 Clinical Neurosciences, University of
Southampton, Southampton, United Kingdom;
2
University Hospital of Southampton, Southampton,
United Kingdom *CR
The Commercial Relationships (CR) Index for Disclosures and the Clinical Trial (CT) Registration Index are at arvo.org/2013/ProgramSummary/Index.
274